This is a boiler plate statement that DI is now apparently using to justify the delay. You appear to be an experienced biotech investor. Wouldn't you agree that companies approaching the release of Phase III data all say something similar, with the only variation being "release of TLD and presentation at a future medical conference." Yet, I cannot find even one example of a company releasing TLD through a journal article. Not one. And you know why? Because top line data is a summary of the full data, and the journal article will contain an analysis of the full data. So it's just nonsense to think that NWBO is going to wait to release data through a journal. Not only would it be the first time this ever happened, but it doesn't make any sense and serves no purpose. Even though the management team collectively has no experience with this phase of drug development, they can't be so naive, or just plain stupid, to think that there is any benefit in their purported strategy to withhold TLD in favor of a journal article. It certainly won't help with regulatory authorities. The FDA's BLA process isn't going to be impacted in the least by a journal article. And any benefit to the stock price will be temporary, because the data is the data and ultimately, if it's clean enough to anticipate FDA approval, the stock price will go up, but if it's murky enough that it will be a close call, then the stock price will be vulnerable to attack. The good news is that at least we are past the point of worrying about a total failure.
I agree with you on the uselessness of calling IR. However, it's interesting in this case the DI is apparently willing to tell certain investors things that, if true, should be in a PR. Like, "we were going to release TLD, but one of our advisors told us to wait for journal publication." At least they can't hide behind the Oct. 5 press release forever...maybe another couple months though.
